Please login to the form below

Not currently logged in
Email:
Password:

Former Pfizer R&D head LaMattina to advise Ziarco

He previously spent 30 years at US pharma firm

Dr John LaMattina ZiarcoUK-based biotech Ziarco has hired former head of R&D at Pfizer, Dr John LaMattina, as a strategic R&D adviser.

Dr LaMattina spent 30 years at Pfizer in total, including four years as president of global research and development from 2003 until his retirement from the US pharma giant in 2007.

Earlier roles he held at Pfizer included senior VP of worldwide development and chief medical officer.

In his new role, he will help Ziarco to advance its development strategies for its investigational compounds to tackle inflammatory and allergic diseases.

These include a H4 agonist that has just completed a phase I study.

In addition to his role at Ziarco, LaMattina is a senior partner at PureTech Venues and serves on the board of directors at Ligand Pharmaceuticals and the scientific advisory board of Trevena Pharmaceuticals.

20th March 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...